World's Best Scientists 2026 revealed!
Franck Morschhauser

Franck Morschhauser

D-Index & Metrics

Medicine

D-Index
94
Citations
37993
World Ranking
10371
National Ranking
323

Franck Morschhauser publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Franck Morschhauser sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 883 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Franck Morschhauser D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Franck Morschhauser sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Franck Morschhauser is affiliated with the University of Lille in France. Their research primarily focuses on fields within medicine, with notable contributions in pathology and forensic medicine, oncology, genetics, molecular biology, and immunology.

The scientist's work extensively covers several specialized topics, including:

  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Viral-associated cancers and disorders
  • CNS Lymphoma Diagnosis and Treatment
  • Cutaneous lymphoproliferative disorders research
  • Monoclonal and Polyclonal Antibodies Research

Franck Morschhauser has published papers in some of the leading oncology and hematology journals. Frequent venues for their publications include:

  • Blood
  • Hematological Oncology
  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances

Co-authorship is a significant element in their research output. Key frequent co-authors are:

  • Emmanuel Bachy
  • Guillaume Cartron
  • Olivier Casasnovas
  • Catherine Thiéblemont
  • Roch Houot

Among notable papers authored or co-authored by Franck Morschhauser are:

  • "The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee" (2022, Blood)
  • "Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial" (2022, The Lancet)
  • "Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma" (2022, New England Journal of Medicine)
  • "Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial" (2020, The Lancet Oncology)
  • "Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma" (2021, New England Journal of Medicine)

Best Publications

  • Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

    P Feugier;A. Van Hoof;C. Sebban;P. Solal-Celigny

  • Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

    Bertrand Coiffier;Barbara Pro;H. Miles Prince;Francine Foss

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

    Franck Morschhauser;John Radford;Achiel Van Hoof;Umberto Vitolo

  • Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

    Gilles Salles;Nicolas Mounier;Sophie de Guibert;Franck Morschhauser

  • Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

    Sylvain Choquet;Veronique Leblond;Raoul Herbrecht;Gérard Socié

  • Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial

    Ralf Trappe;Stephan Oertel;Veronique Leblond;Peter Mollee

  • Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

    Arnaud Jaccard;Nathalie Gachard;Benoit Marin;Sylvie Rogez

  • Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

    Michael Wang;Simon Rule;Pier Luigi Zinzani;Andre Goy

  • Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

    Franck Morschhauser;Hervé Tilly;Aristeidis Chaidos;Pamela McKay

  • Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

    Sandy Amorim;Anastasios Stathis;Mary Gleeson;Sunil Iyengar

  • Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

    Steven Le Gouill;Catherine Thieblemont;Lucie Oberic;Anne Moreau

  • Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

    Martin Dreyling;Armando Santoro;Luigina Mollica;Sirpa Leppä

  • Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

    Maria Corinna A Palanca-Wessels;Myron Czuczman;Gilles Salles;Sarit Assouline

  • Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

    Anas Younes;Catherine Thieblemont;Franck Morschhauser;Ian Flinn

  • Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

    John G. Gribben;Nathan Fowler;Franck Morschhauser

  • Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

    Franck Morschhauser;Nathan Fowler;Pierre Feugier;Reda Bouabdallah

  • SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

    René-Olivier Casasnovas;Michel Meignan;Alina Berriolo-Riedinger;Stéphane Bardet

  • A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

    Harriet S. Walter;Simon A. Rule;Martin J. S. Dyer;Lionel Karlin

  • Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

    Christian Récher;Bertrand Coiffier;Corinne Haioun;Thierry Jo Molina

Frequent Co-Authors

Gilles Salles
Gilles Salles Memorial Sloan Kettering Cancer Center
John Radford
John Radford University of Manchester
Ryan D. Morin
Ryan D. Morin Simon Fraser University
Ranjana H. Advani
Ranjana H. Advani Stanford University
Raoul Herbrecht
Raoul Herbrecht University of Strasbourg
Pauline Brice
Pauline Brice Hôpital Saint-Louis
Peter Johnson
Peter Johnson University of Southampton
Eric Oksenhendler
Eric Oksenhendler Université Paris Cité
Olivier Casasnovas
Olivier Casasnovas Grenoble Alpes University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in Medicine but want to explore alternative or supporting careers in healthcare, several online degree programs offer flexible and affordable options. These pathways can provide valuable credentials and open doors to essential medical roles.

For those drawn to the data side of healthcare, pursuing an online mhi (Master’s in Health Information) degree is a great step. This field focuses on managing patient data and health information systems.

Students seeking entry-level roles should consider affordable medical billing and coding programs. These programs prepare you for fast-growing jobs handling crucial administrative functions in medical settings.

For those interested in nursing careers, you’ll find a range of cheap online nursing programs for RN degrees. If you want to advance and become a nurse practitioner, check out the cheapest online fnp program options for a graduate degree.

These related online programs make it easier to progress in healthcare—no matter your background or budget.

Best Scientists Citing Franck Morschhauser

Trending Scientists

Recently Published Articles